Athira Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA) announces participation in two investor conferences: the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:40 p.m. ET and the Jefferies 2021 London Healthcare Conference available on-demand from November 18 at 4:00 a.m. ET. Both events will feature a fireside chat format. Live webcasts will be accessible through the Investors section of the Athira website, with archived replays available for 30 days. Athira focuses on developing small molecules to restore neuronal health and combat neurodegeneration, particularly in Alzheimer’s and Parkinson’s.

-Stifel 2021 Virtual Healthcare Conference-
- Jefferies 2021 London Healthcare Conference-

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:

Stifel’s 2021 Virtual Healthcare Conference

• Format: Fireside chat
• Date & Time: Monday, November 15, 2021 at 2:40 p.m. ET

Jefferies London Healthcare Conference

• Format: Fireside chat
• Date & Time: Available on-demand starting Thursday, November 18, 2021 at 4:00 a.m. ET

A live webcast of each fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.

For more detail and to register for the events above, please visit https://investors.athira.com/news-and-events/events-and-presentations

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Julie.rathbun@athira.com
206-769-9219

FAQ

When is Athira Pharma's participation in the Stifel 2021 Virtual Healthcare Conference?

Athira Pharma will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 2:40 p.m. ET.

How can I access the Jefferies 2021 London Healthcare Conference presentation by Athira?

The presentation at the Jefferies 2021 London Healthcare Conference will be available on-demand starting November 18, 2021, at 4:00 a.m. ET.

Where can I find the webcast of Athira Pharma's conference appearances?

Webcasts of Athira Pharma's conference appearances can be accessed through the Investors section of their website.

What is the focus of Athira Pharma's research and development?

Athira Pharma focuses on developing small molecules aimed at restoring neuronal health and addressing neurodegeneration, specifically in conditions like Alzheimer’s and Parkinson’s diseases.